ReviewMedical oncology (Northwood, London, England)2025
Emerging roles and therapeutic potential of non-coding RNA in osteosarcoma: a review.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The MDM2-p53 Axis in Osteosarcoma: Current Understanding of Regulatory Mechanisms and Targeted Therapeutic Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS) is recognized as the most prevalent primary malignant bone tumor, characterized by rapid progression, early metastasis, limited efficacy of conventional chemotherapy or radiotherapy, and unfavorable clinical outcomes. Recent studies have highlighted the critical role of non-coding RNAs (ncRNAs), including microRNAs, long non-coding RNAs, and circular RNAs, in the regulation of osteosarcoma biology. The altered expression of these molecules significantly influences tumor cell proliferation, migration, apoptosis, and angiogenesis. Moreover, their dysregulation has been associated with drug resistance and disease recurrence. Given these attributes, ncRNAs are emerging as potential biomarkers for both diagnosis and prognosis, as well as promising therapeutic targets. A more profound understanding of their molecular mechanisms may aid in the development of more effective and personalized strategies for managing osteosarcoma.
Indexed as
Identifiers
40986199What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.